Real-time polymerase chain reaction species specific for Neisseria Gonorrhoeae by Olsen, Merethe Elise
R E A L - T I M E  P O L Y M E R A S E  C H A I N  
R E A C T I O N  S P E C I E S  S P E C I F I C  F O R   
N E I S S E R I A  G O N O R R H O E A E  
 


















Department of Microbiology and Virology 
Institute of Medical Biology 





Department of Microbiology and Infection Control 







The work presented in this thesis was carried out and fully supported by the Department of 
Microbiology and Infection control, University Hospital of North Norway in Tromsø.  
 
I would like to express my gratitude to all of my supervisors, Dr.med Vegard Skogen,  
PhD student Stig Ove Hjelmevoll and Professor Johanna U. Ericson Sollid, for their critical 
review of this thesis, and for guiding me throughout the writing process. Especially thanks to 
Stig Ove Hjelmevoll who conducted the Neisseria gonorrhoeae project and supervised the 
practical work during this study. 
 
And sincerely thanks to “Lederteamet” at the Department of Microbiology and Infection 
control, University Hospital of North Norway in Tromsø. Who approved this project, and 
believing in me as a master student! 
 
I also would like to thank: 
Magnus Unemo at the National Reference Laboratory for Pathogenic Neisseria, Department 
of Clinical Microbiology, Örebro University Hospital, Sweden, for his contribution of N. 
gonorrhoeae strains, supply of illustration and performing sequencing PCR during the clinical 
validation. 
 
Harald Moi, and everyone at Olafia clinic for collection and distribution of clinical samples. 
And thanks to all of them who agreed to be included in this study, and making a clinical 
validation possible. 
 
Kjetil Melby and his colleagues at the Department of Microbiology Ullevål University 
Hospital in Oslo, for performing phenotypic identification during the clinical validation. 
 
Helen Palmer and Lene Berthelesen for providing several N. gonorrhoeae strains and other 
Neisseria species.  
 




Last but not least, I would like to thank my family for all encouragement and support, even 
though being so neglected. Especially thanks to Morten, my better half, for his patient and 
motivation, and taking extra care of Sindre and Villma in such stressful study times.  
  
May 2008  
 





Gonorrhea is a sexually transmitted disease with both medical and social implications, thus 
clinicians urge for rapid, specific and sensitive diagnostic tools. Phenotypic and genotypic 
approaches have been tested with variable outcome. 
Today the gold standard for diagnosing gonorrhea is cultivation combined with phenotypic 
tests. The challenge is that these methods require living bacterial cells and the fastidious N. 
gonorrhoeae survives poorly outside its human host. 
To increase the sensitivity, nucleic acid amplification tests (NAATs) targeting N. 
gonorrhoeae have been developed and are commercially available. However, studies 
evaluating specificity in several of theses methods, have uncovered cross reactivity causing 
false positive results which may have major impacts for the individual. 
The overall aim of this study was to establish and clinically validate a qualitative in-house 
real time Polymerase Chain Reaction (PCR) method targeting porA pseudogene in N. 
gonorrhoeae. Reference strains (n= 32) and clinical isolates (n= 168) of N. gonorrhoeae and 
commensal Neisseria (n= 66) were examined as well as other micro organisms able to 
colonize gonorrhea sampling sites (n= 46).  
Functional and specific primers for the real-time PCR were designed from the porA sequence 
and the in-house real-time PCR amplification was evaluated, and the technical performance 
was found to be both specific and sensitive. The in-house PCR detected all N. gonorrhoeae 
strains included, and showed no cross reactivity with other microbes.  
The Universal Transport Medium (UTM-RT) system was tested for its suitability in 
transporting samples for PCR.  
The clinical validation was performed on 360 samples and compared the outcome from the 
porA PCR and the phenotypic techniques for gonococcal identification. The porA PCR was 
found to be more sensitive than the traditional phenotypic tests, especially in samples from 
sites other then urethra and cervix.   
It can be concluded that the porA pseudogene real-time PCR is species specific for N. 
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Gonorrhea is a sexually transmitted disease caused by bacteria called gonococci. The disease 
was described in ancient times, but until the late nineteenth century it was mixed up with 
syphilis. Eventually microscopy could differ between the organisms and give a reliable 
diagnosis. Human is the only known reservoir for gonorrhea. It is transferred during all acts of 
sexual activity, and an infection cause characteristic symptoms if established. Reliable 
diagnostic tools are important not only because gonorrhea is a severe disease but also because 
the means of spreading will always have a negative social impact on people given the 
diagnosis. Gonococci are fastidious bacteria, and survive poorly outside its human host. Thus 
diagnostic methods have been challenged by the problem of retrieving living bacteria for 
phenotypic tests. There have been several attempts to identify gonococci by specific 
characteristic in its genome, but these have been less successful. Due to its fluctuating 
genome it has been difficult to find a specific target for the gonococci. Here I present an 
attempt to establish a reliable diagnostic tool for reproducible detection and specific 
identification of gonococci in samples from different body sites. 
 
1.1 The genus Neisseria 
Neisseria gonorrhoeae belongs to the family Neisseriaceae in the genus Neisseria. The 
bacteria in the genus are Gram-negative diplococci (except N. elongata which is rod shaped), 
and the only human pathogens are N. gonorrhoeae, causing gonorrhea, and N. meningitidis, 
causing meningococcal meningitis. N. meningitidis may occur in a carrier state in the 
pharynx, but N. gonorrhoeae is never part of the normal human flora, and causes disease 
whenever colonized in its human host.   
N. gonorrhoeae primarily infects the mucosa membrane in the male urethral tract and the 
cervical mucosa membrane in females, but the bacteria may also colonize the mucosa 
membrane in the pharynx, rectum and even cornea of the eye. The commensal Neisseria (i.e. 
N. lactamica, N. sicca, N. cinera, N. flavescens and N. elongata) and the N. meningitidis are 
most common in the mucosa of the pharynx. But there are reports that N. cinera, N. 
lactamica, N. sicca and N. subflava also have been isolated from the genital mucosa 1,2.  
 
 
1.2 Physiology and characteristic structures in N. gonorrhoeae 
N. gonorrhoeae is a fastidious aerobic bacterium. It requires nutritious media for growth and 
prefers humid atmosphere that contain approximately 5 % carbon dioxide. The bacteria have 
an optimal growth temperature of 35-37°C, and have minimal chances to survive at low  
temperatures3. It produces oxidase, catalase and oxidizes glucose if available. N. gonorrhoeae 
do not expose flagella and produces no endospores 3.  
Examined in the microscope, the bacterial cells have a characteristic coffee bean shape with 
adjacent side flattened in the microscope. In older colonies of N. gonorrhoeae, the cells may 
appear swollen and round due to autolysis.   
The cell wall structure of N. gonorrhoeae is similar to other Gram negative bacteria with an 
inner cytoplasmic membrane and an outer membrane composed of proteins, phospholipids, 
and lipopolysaccharide (LPS), and a thin peptideoglycan layer between the inner cytoplasmic 
membrane and the outer membrane. The LPS in the N .gonorrhoeae are referred to as 
lipooligosaccharides (LOS), due to that they consist of a shorter saccharide chain compared to 
the LPS. Several proteins are exposed on the cell surface of the N. gonorrhoeae, pili, porin 
proteins (PorB), Rmp proteins (Reduction modifiable protein) and Opa (opacity protein) 
proteins. They are all thought to have different roles in invasion of the host and virulence 
activity 3,11.  





       
Figure 1: Modified schematic drawing from Danielsson D (Biology of Neisseria gonorrhoeae, 1986) kindly 
provided by Magnus Unemo13 showing N. gonorrhoeae as a characteristic diplococci. The cell wall, bacterial 
chromosome, cryptic plasmid and some of the interesting structures and proteins of the outer membrane (pilus, 




The genomic similarity among the Neisseria species is well reported for the pathogenic 
species. N. meningitidis and N. gonorrhoeae share 80-90% homology in their genomic DNA, 
and their housekeeping genes may show 98% sequence identity 4,5. Despite their high 
genomic similarity there are cellular differences between the two species. One major 
difference is the polysaccharide capsule which only N. meningitidis expresses.  
In 2000 the N. gonorrhoeae strain FA 1090 had its entire chromosome fully sequenced 
2,153,922 base pairs (bp) long (www.ncbi.nlm.nih.gov/sites/entrez). Several plasmids have 
been found in N. gonorrhoea, and different types of plasmids circulate among the strains. A 
cryptic plasmid has been found in a majority of strains, and the rapid spreading of beta-lactam 
resistance is thought to be plasmid mediated 6.  
 
Transformation is the main mechanism for horizontal genetic exchange transfer in N. 
gonorrhoeae, but extra-chromosomally DNA can be transferred by conjugation. 
N. gonorrhoeae is competent throughout the entire lifecycle and donate genetic material to the 
environment by active secretion or by autolysis. With a type IV secretion system, similar to 
type IV found in E. coli, the bacterium can secret DNA to its neighboring cells. The factor 
that triggers the secretion mechanism is poorly documented. Autolysis occurs when the 
bacterium is under unfavorable growth conditions, like lack of nutrients and change in pH. A 
specific enzyme is thought to be responsible for the autolysis process 7. A successful 
transformation is dependent on several factors, and the presence of pili is thought to be 
important in DNA uptake 8. However, transformation in N. gonorrhoeae occurs only if the 
DNA contains a specific sequence, called DNA Uptake Sequence (DUS) 7. The sequence 
comprises of 10 base pairs 5’–GCCGTCTGAA-3’ and is frequently distributed in the 
Neisseria genome7. The above mentioned N. gonorrhoeae FA 1090 has 1965 DUS present in 
its genome 30.  
It has been reported in several studies that genetic exchange occurs between commensal 
Neisseria and pathogenic Neisseria 9,10. A frequent exchange of tbpB sequences (gene 
encodes the TbpB, transfer binding protein) from commensal Neisseria has contributed to 
antigenic variations in N. meningitidis 9. A great number of virulence genes found in 
pathogenic Neisseria have also been found in commensal Neisseria 10. 
 
1.3 Pathogenesis and clinical manifestations of gonorrhea 
Expression of pili is one of many virulence mechanisms in the N. gonorrhoeae. N. 
gonorrhoeae attach to the epithelial cells of the mucosa membrane by its pili, which is 
thought to be the initial step in gonococcal invasion. Figure 2 gives an overview of the 
Neisseria attachment. The OPA proteins can be expressed by a variety of alleles. These 
proteins are responsible for both a tighter attachment and the migration into the host cell. 
Inside the cell the bacteria multiply. Usually they remain in the epithelial layers, but the 
bacteria can cross over into the bloodstream causing disseminated infection. LOS in N. 
gonorrhoeae has endotoxin activity and stimulates the inflammatory response in the host. The 
Rmp proteins are believed to protect other surface antigens due to its production of antibodies 














Figure 2: The figure illustrates the primary attachment of Neisseria to the surface of mucosal epithelial cells 
mediated by the pilus (thin philament). Opa proteins (black dots) cause a tighter interaction. Once attached, the 
bacteria are able to pass through the epithelial layer and exit into bloodstream causing disseminated infections. 
The image is kindly provided by Professor Scott D. Gray-Owen. 
 
An invasion of N. gonorrhoeae primarily affects the urethral mucosa membrane, but mucosa 
membrane in body site as cervix, rectum and pharynx can also be invaded. Invasion of 
pharynx and rectum are often asymptomatic, and asymptomatic carriers can act as a reservoir 
for gonococcal infection but they also risk complicated gonorrhea infection. Gonococcal 
infection of urogenital sites is more frequently symptomatic than asymptomatic. If infections 
are untreated the symptoms often clear within weeks, and an asymptomatic “carrier state” can 
be established 3,11.  
Symptoms of infection occur within 2-7 days and are often more appearing in male than 
females. Gonorrhea is manifested by urethritis, dysuria and purulent discharge from urethra 3. 
In male complicated infections may lead to inflammation of the prostate and testis. And in 
 
female, infection of the endocervix is most common, and may cause vaginal discharge. If the 
infection invades further it may extend through the uterus to the fallopian tubes causing 
inflammation in the tubes and subsequent in the ovaries 3. And a severe infection may cause 
infertility. If N. gonorrhoeae crosses the epithelial layer and enters the bloodstream, this may 
result in septicaemia, which is manifested by pustular skin lesion on extremities and can lead 
to  complication as endocarditis, meningitis and arthritis 3. Another complication caused by N. 
gonorrhoeae is eye infections in newborns infected during passage of the birth canal, 
untreated this can lead to scarring of the cornea3. Once this was a major cause of blindness, 
but today this is rare due to screening and prophylaxis. 
 
1.4 Antibiotic treatments  
Historically, Penicillin was a common antibiotic in the treatment of gonorrhea. Nowadays, 
Penicillin is no longer used because many strains of N. gonorrhea have reduced susceptibility 
to penicillin. Plasmid encoded β-lactamase production is one common resistance mechanism6. 
The spread of such plasmids have contributed to a rapid increase in number of resistant 
strains.  New antibiotics or combinations of drugs must be used to treat these resistant strains. 
According to Norwegian guidelines, ciproxin, ciprofloxacin or oflaxacin are antimicrobial 
agents for treatment of uncomplicated gonorrhoeae. However, an increased resistance to 
ciproxin/ciprofloxasin has been observed during an ongoing test of cure study (Hjelmevoll et 
al., to be published). 
 
1.5 Epidemiology 
In Norway the reported incidence of gonorrhea peeked in the years 1975 and 1976 with about 
15 000 cases of gonorrhea annually. Since then the number of annually reported cases has 
decreased, and today the incidence of gonorrhea is considered low compared to other 
countries. The number of gonorrhoeae infections in 2007, stated by the Norwegian institute of 
public health, was 238. Of the 238 cases 160 were from heterosexuals, while 77 cases were 
reported from homosexuals. Of the 160 heterosexuals, 131 were males and 29 females, and 
Norway was stated as location of infection in 40 % of the males and 31 % of the females. 
Antibiotic resistant gonococci were found in 53 % of the 238 gonorrhea cases.  
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Eye infection caused by gonococci is most common in newborns, but today gonococcal eye 
infections are rare in Norway. The last reported case of eye infection was stated in 1991 by 
Norwegian institute of public health.  
As mentioned, N. gonorrhoeae can cause disseminated infections. However, there are few 
cases reported. Approximately 0.1 – 0.5% of all gonococcal infections may lead to a 
disseminated infection (www.nfi.no, home page of Norwegian institute of public health). 
 
1.6 Detection of N. gonorrhoeae 
There are several ways to identify N. gonorrhoeae, both phenotypic and genotypic. The gold 
standard is still cultivation and microscopy of smear from urogenitalia. The microscopy of 
smear in females is less reliable, then for males, and must be confirmed by culture. A number 
of phenotypic diagnostic techniques have been developed based on; growth requirements of 
specific nutrient and cofactors (auxotyping), enzymatic activity (i.e. Api NH) and serological 
reactivity against surface antigens (i.e. Phadebact monoclonal Test).  These methods have in 
common that they require living bacterial cells, and this is one of the major problems when 
using phenotypic techniques in diagnosing of gonorrhea. The N. gonorrhoeae survives poorly 
outside its human host, and tend to have a low recovery rate from extra genital samples 15. 
Another problem is due to overgrowth of normal flora, especially in sample sites such as 
pharynx, cervix and rectum, which also decreases the sensitivity.  
In the attempt to improve diagnosing of gonorrhea there have been developed nucleic acid 
amplification tests (NAATs) as a supplement to the diagnostics. However, the qualities of 
many of these methods have been evaluated during the last years, i.e. targets as the cppB gene  
on cryptic plasmid has been reported missing from several strains, causing a potentially  false 
negative diagnosis 18, many of the studies have shown variability specificity1,17,18. Even so, 







1.7 The porA pseudogene 
Porins are the most represented outer membrane proteins in the pathogenic Neisseria. N. 
meningitidis is the only species known to express both PorA and PorB, while N. gonorrhoeae 
is known to only express PorB. However, N. gonorrhoeae possesses the porA gene despite of 
not expressing the protein, and the porA has been proposed as pseudogene in N. gonorrhoeae 
5. Phylogentically it seems like these two species share common ancestor, and during 
evolution N. gonorrhoeae had no need for expressing the PorA protein when invading the 
host, leading to a “silencing” of the gene. The lack of PorA expression may indicate that the 
PorA protein is not essential to the survival of the bacteria 12.  
“Silencing” of the gene is caused by an inactivation mutation in the promoter region, and 
frame shift mutations in the amino acid coding region of the gene 13. Due to diversity in the 
porA gene between the pathogens, the porA pseudogene has been proposed as a suitable target 
for nucleic detection of the N. gonorrhoeae12-14  
 
1.8 Background 
In our laboratory diagnosing gonorrhoeae is based on cultivation and phenotypic 
identification. In optimized conditions this has a high specificity and fairly good sensitivity 
for detection of N. gonorrhoeae. However,  the recovery of N. gonorrhoeae from clinical 
samples is influenced by pre-analytic risk factors such as, sampling, sample site, temperature 
variations during transport, transport duration and transport media.  
The agar plate used for cultivation in our laboratory is selective for N. gonorrhoeae, but 
several other bacteria and fungi find nourishment in this agar. This complicates the detection 
of gonococcal colonies. Furthermore the cultivation combined with the phenotypic detection 
tools can be time consuming.  
N. gonorrhoeae sampled from pharynx and rectum have a lower recovery rate compared to 
samples from urogenitalia when cultivated 15. The transport media consists of a charcoal agar, 
and a purified cotton swab (Amies Charcoal, COPAN, Italy), but this agar is not optimal for 
the nutritional requirements of N. gonorrhoeae. The viability of the bacteria is partly 
maintained if the samples arrives the laboratory within 24 hours 16, but this is not always the 
case for samples sent by practitioners from rural areas. 
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A genotypic approach to diagnose gonorrhoea is proposed as a supplement to increase the 
sensitivity. As mentioned, i.e. nucleic amplification tests (NAATs) require only intact DNA. 
This might reduce the impact of the pre-analytic risk factors. Furthermore compared to 
cultivation the NAAT might decrease the time from receiving the sample to diagnosing 
gonorrhoea.  
There are several commercial NAATs available, but studies have reported low specificity in 
many of these; some auxotypes or individual strains are not identified as N. gonorrhoeae, and 
some Neisseria species can be misclassified as N. gonorrhoeae 1,17,18. Cross reactivity is 
specially the case when sampling from pharynx, where commensal Neisseria species share 
habitat with the human pathogen Neisseria species. 
One of the major problems in developing NAATs for detection of N. gonorrhoeae was 
finding a specific target sequence. N. gonorrhoeae is naturally competent and the genetic 










2 AIMS OF STUDY 
The overall aim was to establish a validated species specific qualitative real-time Polymerase 
Chain Reaction (PCR) assay for detection of N. gonorrhoeae.  
 
I. To design species specific primers to detect N. gonorrhoeae. 
 
II. To perform a technical evaluation of the in-house PCR by determining efficiency and 
detection limit for the PCR and also its analytic specificity and sensitivity. 
 
III. To find and test the suitability of a transport media containing a buffer that preserves the 
DNA and comprises of swabs suitable for different sample sites; cervix, urethra, rectum 
and pharynx. In addition it should be suitable for the transport of other bacteria and 
viruses, with already established in-house PCR in our laboratory.  
 
IV. To perform a clinical validation of the in-house PCR by comparing it to phenotypic 












3 MATERIALS  
3.1 International Neisseria reference strains 
In total we analyzed DNA from 44 International Neisseria reference strains with the in-house 
PCR. They were collected from American Type Culture Collection (ATCC), Culture 
Collection University of Gothenburg (CCUG), National Collection of Type Cultures (NCTC), 
World Health Organization (WHO), Swedish Reference Laboratory for Pathogenic Neisseria, 
and Statens Serum Institut (SSI) in Denmark. These reference strains included Neisseria 
gonorrhoeae (n=32), Neisseria meningitidis (n=4), Neisseria sicca (n=2), Neisseria subflava  
(n=1), Neisseria flavescens (n=1), Neisseria mucosa (n=2), Neisseria lactamica (n=1), and 
Neisseria cinera (n=1).The N. gonorrhoeae reference strains originated from different 
geographic areas worldwide and have been isolated during the last four decades. And in 29 of 
the 32 N. gonorrhoeae reference strains the entire porA pseudogene has been sequenced. 







Table 1: Reference strains and reference number, year of isolation are stated where available.  
 
Species Reference ID Year 
N. gonorrhoeae  ATCC 23051 1966 
N. gonorrhoeae  ATCC 19424 1966 
N. gonorrhoeae  CCUG 42289 1973 
N. gonorrhoeae  CCUG 42290 1973 
N. gonorrhoeae  CCUG 42287 1978 
N. gonorrhoeae  CCUG 13572 1983 
N. gonorrhoeae  CCUG 13574 1983 
N. gonorrhoeae  CCUG 13576 1983 
N. gonorrhoeae  CCUC 13577 1983 
N. gonorrhoeae  CCUC 13578 1983 
 
Species Reference ID Year 
N. gonorrhoeae  CCUC 13579 1983 
N. gonorrhoeae  CCUG 13583 1983 
N. gonorrhoeae  CCUG 13584 1983 
N. gonorrhoeae  CCUG 13586 1983 
N. gonorrhoeae  CCUG 15821 1984 
N. gonorrhoeae  CCUG 15823 1984 
N. gonorrhoeae  ATCC 31426 1990 
N. gonorrhoeae  CCUG 13581 1995 
N. gonorrhoeae  CCUG 33978 1995 
N. gonorrhoeae  CCUG 33979 1995 
N. gonorrhoeae  CCUG 34327 1995 
N. gonorrhoeae  CCUG 34447 1995 
N. gonorrhoeae  CCUG 43069 1995 
N. gonorrhoeae  CCUG 41813 1996 
N. gonorrhoeae  CCUG 36701 1996 
N. gonorrhoeae  CCUG 36702 1996 
N. gonorrhoeae  ATCC 49226 1997 
N. gonorrhoeae  WHO-D 1998 
N. gonorrhoeae  CCUG 41810 1999 
N. gonorrhoeae  CCUG 41811 1999 
N. gonorrhoeae  CCUG 41812 1999 
N. gonorrhoeae  CCUG 42285 NA 
N.cinera CCUG 2156 1973 
N. flavescens NCTC 8263 1952 
N. lactamica CCUG 5853 1976 
N. meningitidis ATCC 13090 NA 
N. meningitidis  ATCC 13102 NA 
N. meningitidis  CCUG 41446 1998 
N. meningitidis  CCUG 41447 1998 
N. mucosa NCTC 10774 1971 
N. mucosa  NCTC 10777 1971 
N. sicca ATCC 9913 1985 
N. sicca  CCUG 34456 1995 
N. subflava ATCC 19243 1985 








3.2 Clinical isolates 
In total we examined 168 clinical isolates of N. gonorrhoeae, and 54 clinical isolates of other 
Neisseria species. DNA from all the clinical isolates was analyzed by the porA PCR. 
Of the 168 N. gonorrhoeae isolates 76 were cultured in Archangelsk Russia in 2004. These 
isolates had initially been cultured on non selective media (NPO Microgen, Stavropol, Russia) 
and identified as N. gonorrhoeae by characteristic colony morphology, Gram staining and 
oxidase reaction 19. In addition they were also confirmed as N. gonorrhoeae at the Department 
of Microbiology and Infection control, University Hospital of North Norway, by cultivation 
on selective media, oxidase reaction, sugar oxidation and a specific monoclonal antibodies 
test. This is described in chapter 4.2 Phenotypic identification of N. gonorrhoeae. 
Furthermore 14 were isolated at Department of Microbiology and Infection control, 
University Hospital of North Norway, in 2003-2004 and 9 isolates were received from 
Norwegian Organization for Surveillance of Antibiotic Resistant Micro organisms (NORM). 
The isolates were identified as mentioned above. 
We received 13 isolates from Lene Berthelsen at SSI in Denmark, identified by cultivation on 
selective medium and MINIBACT-N  and 5 isolates provided by Helen Palmer 1 and 51 
Swedish isolates from 1998-2001 with known porA pseudogene sequence were provided by 
Magnus Unemo 13. 
In addition clinical isolates (n=54) of other Neisseria species were included. N. gonorrhoeae 
subspecies kochii (n=4), Neisseria meningitidis (n=7), Neisseria sicca (n=7), Neisseria 
subflava (n=11), Neisseria flavescens (n=3), Neisseria mucosa (n=5), Neisseria lactamica 
(n=7), Neisseria cinera (n=7), Neisseria caviae (n=1), Neisseria animalis (n=1), and 
Neisseria polysaccharea (n=1). These isolates were identified by sugar oxidation, oxidase 
reaction and API NH (BioMerieux, La Balme-les-Grottes, France). Isolation of DNA was 
performed as described in chapter 4.3.1 Isolation of DNA. 
 
 
3.3 Heterogeneous control strains 
In total we examined DNA from 47 other micro organisms as well as human DNA. The 
heterogeneous control strains were used to uncover cross-reaction with DNA from other 
organisms than Neisseria species. The in-house PCR was tested with DNA from the following 
organisms: Gram negative bacteria (n=18), Gram positive bacteria (n=23), fungus (n=1), 
viruses (n=4) and human DNA. More details of the strains are listed in Table 2. Isolation of 
DNA was performed as described in chapter 4.3.1 Isolation of DNA. Bacteria and viruses 
commonly found in the normal flora in sites as cervix, pharynx, rectum and urethra, were 
selected for specificity testing. In addition, bacteria and viruses with already established in-
house PCRs were added to the test panel as they are at risk of contaminate the environment of 
our laboratory. 
 
Table 2: Heterogeneous control strains used in this study; media and culture conditions 
Heterogenous control strains ID Media** and culture condition  
Acinetobacter baumannii  ATCC 19606 Lactose agar (37°C) 
Actinomyces odontolyticus ATCC 17929 Anaerobic agar (37°C anaerobic milieu) 
Bordetella pertussis ATCC 8467 Chocolate agar (35°C CO2)  
Candida albicans ATCC 10231 Blood agar (37°C) 
Chlamydia trachomatis Tebu bio * Purified genomic DNA from manufacture 
Citrobacter freundii ATCC 43864 Lactose agar (37°C) 
Corynebacterium diphteriae  ATCC 19409 Chocolate agar     (37°C) 
Eikenella corrodens CCUG 2138 Blood agar (37°C) 
Enterobacter sakazakii ATCC 29544 Lactose agar (28°C) 
Enterococcus casseliflavus ATCC 25788 Blood agar (37°C) 
Enterococcus faecalis ATCC 19433 Blood agar (37°C) 
Enterococcus faecium ATCC 19434 Blood agar (37°C) 
Enterococcus flavescens ATCC 49996 Blood agar (37°C) 
Enterococcus gallinarum ATCC 49608 Blood agar (37°C) 
Enterococcus saccharolyticus ATCC 43076 Blood agar (37°C) 
Escherichia coli ATCC 25922 Lactose agar (37°C) 
Gardenella vaginalis  ATCC 14018 Blood agar (35°C CO2) 
Haemophilus influenzae ATCC 35039 Chocolate agar  (35°C CO2) 
Helicobacter pylori ATCC 43504 Chocolate agar (37°C microaerophilic milieu)  
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Heterogenous control strains ID Media** and culture condition  
Klebsiella pneumoniae ATCC 13883 Lactose agar (37°C) 
Lactobacillus plantarum ATCC 4008 Blood agar (37°C) 
Legionella pneumophila ATCC 33153 Chocolate agar   (35°C CO2 Humide milieu) 
Listeria monocytogenes serot. 1  ATCC 19111 Blood agar  (37°C mikroaer) 
Micrococcus diversus ATCC 25590 Blood agar (28°C) 
Micrococcus luteus ATCC 9341 Blood agar (37°C)  
Moraxella catarrhalis ATCC 23246 Blood agar (37°C) 
Moraxella osloensis ATCC 10973 Blood agar (37°C)   
Mycplasma pneumoniae M183p27 Purified DNA donated by Linda B.Heide 
Proteus mirabilis ATCC 35659 Lactose agar (37°C) 
Pseudomonas aeruginosa ATCC 27853 Lactose agar (37°C) 
Rhodococcus equi  ATCC 6939 Blood agar (37°C)   
Staphylococcus aureus ATCC 25923 Blood agar (37°C)   
Staphylococcus aureus (MRSA) ATCC 43300 Blood agar (37°C)   
Staphylococcus epidermidis ATCC 12228 Blood agar (37°C)   
Staphylococcus lugdunensis ATCC 49576 Blood agar (37°C)   
Staphylococcus saprophyticus ATCC 15305 Blood agar           (37°C)   
Streptococcus gruppe B ATCC 12386 Blood agar           (37°C) 
Streptococcus mutans ATCC 25175 Blood agar           (37°C) 
Streptococcus pneumoniae ATCC 6305 Blood agar           (37°C) 
Streptococcus pyogenes gr.A ATCC 19615 Blood agar           (37°C) 
Streptococcus salivarius ATCC 13419 Blood agar           (37°C) 
Ureaplasma urealyticum ATCC 27618 Mycoplasma Broth   (37°C anaer.) 
Herpesvirus 1 Patient samples Provided by DNA by Linda B.Heide  
Herpesvirus 2 Patient samples Provided by DNA by Linda B.Heide  
Metapneumovirus Patient samples Provided by DNA by Linda B.Heide  
Rhinovirus Patient samples Provided by DNA by Linda B.Heide  
Human DNA Patient samples Provided by DNA by Linda B.Heide  
 
*(Le Perray en Yvelines, France). 
**All media were produced in-house at the Department of Microbiology and Infection control, University 





3.4 Clinical samples 
In total 360 samples from 242 individuals were included in the study, with 284 samples from 
185 males and 76 samples from 57 females. The distribution of samples and sample sites 
among males and females are listed in Table 3.  All clinical samples were analyzed by the 
porA PCR and phenotypic diagnostic tools. 
All individuals with suspected infection of gonorrhea were included, in total 269 individuals 
participated. 
 











Male 95 80 109 0 284 
Female 14 4 10 48 76 
Total 109 84 119 48 360 
 
The samples were collected in a period from January 2006 through May 2006, and were taken 
from varying localizations; urethra, rectum, pharynx and cervix, depending on the case 
history. The recruiting of patients and sample collection were performed by the Olafia clinic 
in Oslo, Norway. The samples were brought to the Department of Microbiology Ullevål 
University Hospital in Oslo, Norway (located 3 km in distance from Olafia) for phenotypic 
diagnostics and to the Department of Microbiology and Infection control, University Hospital 
of North Norway in Tromsø (located 1640 km in distance from Olafia),  for analysis by porA 
PCR.  
The samples for PCR were collected using appropriate swabs that were placed and transported 
in 3 ml Universal Transport Medium UTM-RT transport media (Copan, Italy). The urethral 
flocked swab was used for sampling in the urethra, and the endocervical flocked swab was 
used to take samples from the cervix, rectum and pharynx. All samples were stored at 4°C 
before shipping them with regular mail. 
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In parallel identical swabs were taken from the same sites and placed in a M40 transport 
media (Copan) for phenotypic diagnostic. The samples were stored maximum 3 hours at room 
temperature before the laboratory received them. 
The samples for phenotypic diagnostics were consistently taken before the samples for PCR 
to avoid interference with the validated routine diagnostic. 
 
3.5 UTM-RT system  
The UTM-RT transport system (Copan, Italy) consists of a polypropylene container with 3 
mL transport buffer in combination with one of several flocked swabs available for different 
sample sites. After sampling, the respective swabs should be placed in the buffer. According 
to the manufacture the buffer contains the following ingredients; Modified Hank’s Balanced 
Salts, Bovine Serum Albumin, Gelatin, Sucrose, L-glutamic acid, Hepes, Phenol Red, 
Amphotericin and Colistin. Phenol Red works as a pH indicator. Hepes works as a buffer. The 
























4.1 Growth media 
All International Neisseria reference strains and clinical isolates of Neisseria species were 
cultivated for 24 to 48 hours at 37°C in 5% CO2 on non-selective chocolate agar.  
The bacteria and fungi, which constitute the heterogeneous control strains, were cultivated 
from frozen stocks (-70ºC) by using suitable media and incubation conditions as described in 
table 2. 
 




Anaerobic Basal Agar (Oxoid Ltd, Basingstoke, UK) defibrinated 
horse blood, distilled water. 
Blood agar 
 
Blood Agar Base No2 (Oxoid Ltd, Basingstoke, UK), distilled water. 
Chocolate agar GC-Agar Base Medium CM367B (Oxoid Ltd. Basingstoke, UK), 
distilled water, defibrinated horse blood, glucose solution 25 %  and 
Vitox solution (Oxoid Ltd, Basingstoke, UK). 
Lactose agar Tryptose blood agar base (Oxoid Ltd, Basingstoke, UK) Lactose 
LP0070, bromtymolblue. 
Modified Thayer-Martin agar GC-Agar Base Medium CM367B (Oxoid Ltd. Basingstoke, UK), 
distilled water, defibrinated horse blood, glucose solution 25 % and 
Vitox solution (Oxoid SR090H and SR090A). Colistin 6.0, 




PPLO Broth (Difco, USA), Yeast Autolysate(Oxoid Ltd, Basingstoke, 
UK), phenolred 0.2 %, Horse serum (Gibco, USA), Urea (Merck, 
USA) Ampicillin 100 mg/mL, Amphotericin 5 mg/mL, 5 MHCL, 




4.2 Phenotypic identification of N. gonorrhoeae. 
The following protocols are adapted from the Department of Microbiology and Infection 
control, University Hospital of North Norway, which uses them as a part of the routine 
diagnosis of gonorrhea. In addition they perform antibiotic susceptibility testing but this was 
not performed in this study, and therefore the testing is not described. 
 
4.2.1 Modified Thayer-Martin agar plate 
Inoculated plates are incubated for 24 to 48 hours at 37°C in 5% CO2.  N.gonorrhoeae 
grows in this agar by medium sized grayish colonies 20. Contents of the agar plate are 
listed in table 2. 
 
4.2.2 Oxidase protocol 
Oxidase reduction is based on the bacteria’s ability to produce enzymatic oxidase. In the 
presence of enzyme, the reagent tetramethyl-p-phenylenediamine (Oxoid) oxidises, and this is 
visualized by change of colour of the reagent. In this study, the reagent containing phenol 
blue, form a complex with the oxidase enzyme and a bright blue colour appear 21.  
 
Procedure: 
1. Add a drop of reagent on filter paper. 
2. Inoculated the suspected colony. 
3. Instant appearance of blue color indicates presence of oxidase. 
 
Evaluation: 




4.2.3 Gram staining protocol  
Gram staining is based on bacteria’s ability to retain color in the bacteria cell wall. The 
reagents are Crystal violet, Gram’s iodine, Safranin (Becton Dickinson) 96% ethanol and 
saline. Crystal violet and Gram’s iodine interact and produces a complex inside the cell. The 
cell wall of gram positive bacteria contains a thick peptideglycan layer, and they do not 
decolorize by alcohol. The cell of gram positive bacteria is stained violet. The cell wall of the 
gram negative bacteria has a different structure, and will decolorize when exposed to alcohol. 
The gram negative bacteria are stained Safranin red 22.  
 
Procedure: 
1. Add one drop of saline solution on a slide. 
2. Harvest and blend suspect colony in the saline solution. 
3. Air dry the slide, and then heat it to firmly mount the bacteria on the slide. 
4. Add the primary stain crystal violet and incubate 1 minute. This step stains all cells 
violet.  
5. Add Gram’s iodine, for 30 seconds. This fixes the crystal violet to the bacterial cell 
wall. All cells remain violet.  
6. Wash with ethanol to decolorize.  
7. Add the secondary stain, safranin, and incubate 1 min 
8. Wash with water for a maximum of 5 seconds.  
9. Gently wipe the slide to remove excess water. 
10. Use a microscope to evaluate the result. 
 
Evaluation: The Gram positive bacteria stain purple, while the Gram negative bacteria stain 
pink. In the microscopy the N.gonorrhoeae are pink diplococci, coffee bean shaped. 
 
 
4.2.4 Phadebact Monoclonal GC Test protocol  
Phadebact Monoclonal GC Test (Bactus AB, Sweden) is a co agglutination test. The 
antibodies in the WI and WII/WIII reagents react with group specific parts of a membrane 
protein called Protein I.  When a sample containing N. gonorrhoeae is mixed with the reagent, 
antigens on the surface of the gonococci bind to the corresponding antibodies. The 
agglutination is visible to the naked eye 23. The reagents are WI Gonococcal Reagent (In test 





1. Make a suspension of the suspected N. gonorrhoeae colonies in 1.5 ml saline in a 
tube. 
2. Mix the suspension lightly. 
3. The suspension is heated in boiling water for at least 5 minutes. 
4. Cool suspension to room temperature. 
5.  Place drops of the heat treated suspension on the slide. 




Positive result: Agglutination in the WI or/and WII/WIII-reagent.  
Negative result: No agglutination with the any of the reagents. 
 
4.2.5 Carbohydrate metabolism protocol  
 The species in the Neisseria metabolize different carbohydrates, and the metabolic product is 
acid. Suspected colonies are plated on different agars containing; GC-Agar Medium (Oxoid 
Ltd, Basingstoke, UK), distilled water, NaOH, phenolred, L-glutamin (Sigma- Aldrich, USA), 
Iron-nitrate (Merck, USA) and a carbohydrate (glucose, maltose, lactose and saccarose). 
When a carbohydrate is oxidized acid is the product, and this is visualized by a pH-indicator, 





1. Harvest colonies after 18-24 hour of incubation. 
2. Place the suspect colonies on the different agar plates. 
3. Place the inoculated agar plates in a humid compartment. 
4. Incubate 18-24 hour in 37 °C.  
 
Evaluation: 
Positive reaction: Yellow color in the agar surrounding the colonies.    
Negative reaction: No color change of the agar. 
 
4.2.6 API NH protocol 
API NH (BioMeriéux, La Balme-les-Grottes, France) is used to identify Neisseria species, 
Haemophilus species og Moraxella catarrhalis. It is based on biochemical properties in the 
metabolism of the bacteria. The test strip has 10 wells which contain different dehydrated 
substrates, and are able to perform 12 identification tests (enzymatic reactions or sugar 
fermentation), and in addition detect penicillinase production. According to manufacture; 
after incubation with bacteria suspension, a metabolic reaction is visualized as change of color 
in the well. Evaluation of the test result can be performed manually or by using the API LAB 
software (ATB). The reagents are API NH test-kit, 0.9 % saline, JAMES reagent, ZYM B and 
Mineral oil (BioMeriéux, La Balme-les-Grottes, France).  
 
Procedure: 
1. Harvest colonies and makes a 4.0 McFarland suspension in 3 ml saline. 
2. Tilt the test strip and add 50 µl to the wells from PEN including URE. 
3. Add additionally mineral oil from PEN including URE. 
4. Add 150 µl to the wells from LIP including β-GAL. 
5. Seal of the strip with the enclosed lid and place the strip in humidity chamber. 
6. Incubate for 2 hours in 37°C. 
7. Compare the color change according to manufactures instructions. 
 
8. When LIP reaction is positive, the well ProA is predicted negative and no reagents are 
added. 
9. When LIP reaction negative add 1 drop of ZYM B to well LIP including well PAL, 
and add 1 drop of James reagent to well β-GAL.  
 
Evaluation:  
1. Compare the color change according to manufacture’s instructions. 




4.3 Genotypic identification of N. gonorrhoeae 
4.3.1 Isolation of genomic DNA 
Two different robots were used to isolate genomic DNA; BioRobot M48 from Qiagen 
(Hilden, Germany) and TECAN MiniPrep-75 automated Robot (Genpoint, Norway). In 
general the principle for isolation of genomic DNA is incubation of a suspension of bacteria 
cells which are mixed with a lysis buffer, magnetic beads, and washing solutions. After lysis 
of the bacteria cells the DNA is bound to the beads and is then washed to remove potential 
contaminants.  The DNA is released from the beads and resuspended in elution buffer (i.e. 
sterile water). However, the isolation procedure in the TECAN MiniPrep differs from this by 
an additionally step of binding of cells to magnetic beads,  before wash and lysis of the cells. 
Thereafter, the DNA is bound to magnetic beads and washed before resuspension in sterile 
water. Isolation for both robots was performed as recommended from manufacture.  
 
I. BioRobot M48.  
All International Neisseria reference strains, clinical isolates and heterogeneous control 
strains were initially suspended in 200 µl TE-buffer pH 8 (Ambion, Austin TX, USA) to 
approximately 1.5 × 108 Colony Forming Units (CFU)/ml before isolation of DNA. All 
viruses were suspended in a virus in-house transport medium made from Minimum 
Essential Medium (Gibco, Carlsbad Calif), Hepes buffer (Gibco) and Gentamycin 
(Gibco). Isolation of DNA was performed using the MagAttract DNA tissue kit with the 
Infectious disease protocol and an elution volume set to 100 µl.  A known positive 
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processing control (PPC) containing cell suspension of ATCC 19424 N. gonorrhoeae and 
a known negative processing control (NPC) containing water was included in each 
isolation to verify the isolation process. 
 
II. TECAN MiniPrep-75 automated Robot. 
Isolation of DNA from clinical samples in UTM RT was performed with TECAN 
MiniPrep automed Robot by using the Bugs’n Beads kits. Isolation volume was 700 µl 
and elution volume was 100 µl. The robot also performed the set up for the PCR reaction, 
with 11.5 µl template and 13.5 µl reaction solutions (Total 25 µl) for each PCR sample. 




4.3.2 Real-time PCR assay 
In general PCR is amplification of a specific DNA sequence by using primers which bind to 
complementary sequences in the target DNA. By real-time PCR it is possible to monitor the 
progress of the PCR, since data is collected throughout the process. TaqMan® or SYBR® 
Green chemistry can be used to detect PCR Product (amplicon).  
In this study we used TaqMan® chemistry combined with the ABI™ SDS 7900 HT Fast 
Real-Time PCR System (Applied Biosystems Foster city, California).  
TaqMan® chemistry is based on measuring increase of fluorescence. The target probe has a 
fluorescent dye (reporter) bound in the 5’- position and a quenching dye (quencher) in the 3’ 
position. If the probe anneals to a specific target sequence, it is cleaved by the 5’ nuclease 
activity in the Taq® DNA Polymerase as the primer is extended. And during accumulation of 
the PCR product the fluorescence intensity from the probe increases. If the probe does not 
anneal the reporter dye is quenched by the quenching dye. The increase in fluorescence is 
proportional to the amount of amplicons.   
Fast real-time PCR (often called fast cycle PCR) differs from Standard real time PCR due to 
properties in the polymerase used in the Fast Universal PCR Master Mix (reaction solution). 
The polymerase does not require a long activation step and with increased ramping of 
temperature the Fast real time PCR protocol runs 40 cycles within 35-55 minutes (Standard 
 
real-time PCR protocol often runs 40 cycles within 90 minutes). However, the principle 
remains the same; denaturation of template DNA occurs due to high temperature, and then by 
lowering the temperature primers hybridize to the complementary DNA sequence. DNA 
polymerase will extend the annealed primers by deoxy nucleoside triphosphates (dNTPs) 
present in the reaction solution. A series of 25-40 cycles results in an exponential 
amplification of the specific DNA sequence flanked by specific primers. In a 100 % efficient, 
PCR the DNA copies will increase by 10-fold in 3.33 cycles.  
 
4.3.3 Design of primers and probes 
The porA PCR targets a specific sequence in the region of the porA pseudogene in the 
genome of N. gonorrhoeae. The design of primers and probes was performed by Stig Ove 
Hjelmevoll 25 In general the procedure of primer/probe design is finding a sequence that is 
specific for the target of interest (in this case N. gonorrhoeae). By comparing (BLASTn) the 
sequence of the entire gene to all genetic sequences deposited in genome databases 
(GenBank®), a specific region of the gene can be identified. This specific sequence is then 
used to design primers and probe. It is recommended to design primers and probe in a region 
with low Guanine/Cytosine content (20-80 %). The primers should be close to the probe and 
amplify short sequences within the target sequence, 50 to 150 bp in amplicon size. The 
melting temperature (Tm) for the primers should be 58-60°C and 68-70°C Tm for the probe. 
(Guidelines from Applied biosystems, Foster city, California.) 
However, the porA primers and probe were designed as a TaqMan® assay by using Primer 
Xpress™ 2.0 (Applied Biosystems) according to manufacturer’s guidelines. The primers and 
probe sequences and the amplicon were compared to porA pseudogene sequences from a 
previous study 13 as well as all the genetic sequences deposited in GenBank®.  Table 5 shows 










Table 5: Primer and probe sequences used for targeting the N. gonorrhoeae porA 
pseudogene.  
Name primer/probe Sequence 5’-3’ 
Forward primer porA-F GTTTCAGCGGCAGCATTCA 




*FAM is the fluorescent reporter dye and BHQ-1 (BlackHole Quencher one) is the quenching dye. 
 
4.3.4 PCR conditions 
The porA reaction solution contained TaqMan® Fast Universal PCR Master Mix (2×) No 
AmpErase® UNG and in addition RNAse Free water, primers, probes and an internal 
amplification control (IAC). The porA primers and probe were optimized as recommended by 
Applied Biosystems, and a final concentration of 900 nM of each primer and 200 nM of the 
porA probe was found to be optimal. In addition an internal amplification control (IAC) and 
an IAC probe (100 nM final concentration) were added to the reaction solution. The IAC 
function as control of inhibition of the PCR reaction, and was expected to be amplified in all 
negative samples. The IAC is described in detail below in chapter 4.3.5 
For the bacterial strains and the clinical isolates, the reaction volume was 25 µl, with 20 µl 
reaction solution and 5 µl template. For the clinical samples the reaction volume was also 25 
µl, with 13.5 µl reaction solution and 11.5 µl template. All templates were run in parallel, and 
in addition each PCR analysis was run with a known positive template control (PTC) 
containing Quantified N. gonorrhoeae DNA (Tebu-bio, Le Perray en Yvelines, France) and a 
known negative template control (NTC) containing water to test the reaction solution.   
The FAST-PCR protocol was run by: 
• 20 seconds at 95°C to activate the Taq DNA polymerase. 
• 1 second in 50 cycles of 95° to denaturated DNA. 
• 20 seconds in 60° C to anneal and extend primers. 
The FAST-PCR protocol is run within 45 minutes. The primers amplify a 102-bp fragment of 
the porA pseudogene. 
 
 
4.3.5 Internal Amplification Control  
The internal amplification control (IAC) is a PCR product added to the reaction solution to 
uncover the presence of inhibitors of the PCR reaction. The porA primers recognise and 
amplify the IAC, creating a 225 bp amplicon (figure 1). The amplicon is detected using a 
TaqMan®  probe (IAC-P) which anneals specifically to an internal part of the IAC sequence. 
In all negative samples, or in samples with very low amount of target DNA, the IAC would be 
amplified. If the IAC was not amplified in gonorrhoea negative sample, the samples were 
diluted 1:2 and then restested diluted and undiluted. To avoid primer competition between the 
IAC and target DNA, the amount of IAC was kept as low as possible in the reaction solution. 
The IAC was not quantified but optimized to give cycle threshold values from 36 to 39. 
 
 
The IAC was made by using composite primers based on the primers for the porA 
pseudogene. These composite primers is constructed by a porA primer sequence (porA 
forward primer or reverse primer) in the 5‘-end, and  in the 3‘-end a sequence from GEM®-
luc plasmid (Promega Madison, Wi). To amplify the selected region of the plasmid we used 
50 nM of the composite primers, and added 5 µl of a 10-4 dilution of the pGEM®-luc plasmid 
in a total volume of 50 µl reaction solution with no UNG. The IAC-PCR protocol was run at 
GeneAmp® PCR system 9700 (Applied biosystems) and contains the following steps: 
• 10 minutes activation step in 95°C.  
• 15 seconds denaturation step in 40 cycles of 95°C. 
• 1 minute annealing in 60°C. 











Figure 3: A schematic view illustrating the detection of IAC in the reaction solution. The IAC (blue and red 
parallel lines) and the IAC probe and the porA- primers. The GCic composite primers are not present in the 
reaction solution but shown to illustrate the connection to the IAC and the target primers.  F: Flurophore, Q: 




Table 6: Primers and probe sequences for production and detection of the IAC.  
Name Primer/Probe Sequence 5’-3’ 
Forward primer GCic-F  GTTTCAGCGGCAGCATTCATGGTCTGACAGTTACCAATGCTTAA
Revers primer GCic-R  CCGGAACTGGTTTCATCTGATTGGCTGGCTGGTTTATTGCTG 
Probe IAC-P*  Yakima yellow-CCATAGTTGCCTGACTCCCCGTCG-DarkQuencher 
* The probe is used to detect IAC product added in the porA reaction solution. 
 
 
4.3.6 Efficiency of PCR 
For efficiency (E) calculation we used a dilution series of quantified N. gonorrhoeae DNA 
from Tebu-bio (Le Perray en Yvelines, France). Based on the dilution series, a standard curve 
was generated by the software in ABI SDS 7900 HT® (Applied Biosystems, Foster city, 
Calif.). Efficiency was calculated using the formula: E = 10 -1/slope -126, where slope refers to 





GCic Composite reverse primer 
GCic Composite forward primer 
 
Furthermore the efficiency of the DNA isolation methods was estimated.  The ATCC 19424 
N.gonorrhoeae was suspended in phosphate buffered saline to 0.5 McFarland (approximately 
1.5 × 108 Colony Forming Units (CFU)/ml 3 . 
The suspension was then diluted 10-1 through 10-7 and from each of the dilution: 
• 100 µl was plated on modified Thayer Martin Medium and incubated overnight at 
37°C in the presence of 5% CO2. 
• 100 µl was transferred to 3 mL UTM RT buffer (Copan, Brescia, Italy) and Stored 
overnight at 4°C. The next day 200 µl was used to prepare DNA on the BioRobot 
M48, and 700 µl was used to prepare DNA on the TECAN MiniPrep automed Robot. 
 
4.3.7 Detection limit of PCR 
The detection limit of the porA pseudogene PCR (porA PCR) was determined by using 
quantified N. gonorrhoeae DNA from Tebu-bio, containing 1.3 x 104 DNA copies/µl. The 
quantified DNA was diluted in TE-buffer in a dilution series of 1:10 to find the lowest 
detectable concentration. This was performed three times. 
 
4.3.8 Robustnes of PCR 
We tested robustness of the PCR by keeping the reaction solution volume constant at 13.5 µl, 
and varying the sample volume from 9 µl to 15 µl in 1 µl increments. 
 
4.3.9 Interpretation of PCR results 
The results from the porA PCR were interpreted according to the software guidelines from the 
manufacture (Software ABI™ SDS 7900 HT Fast Real-Time PCR System, Applied 
Biosystems). However, all reactions with signal from the target porA probe were assigned 
positive. All reactions without signal from the target probe and with amplified IAC were 
assigned negative. Reactions without signal from both the target probe and the IAC probe, 







4.4 Clinical validation of the porA PCR 
The clinical validation of the porA PCR method were performed in collaboration with  
• Olafia clinic, Oslo, Norway. 
• The Department of Microbiology Ullevål University Hospital, Oslo, Norway. 
• The Department of Microbiology and Infection control, University Hospital of North 
Norway, Tromsø, Norway. 
• National Reference Laboratory for Pathogenic Neisseria, Department of Clinical 
Microbiology, Örebro University Hospital, Örebro, Sweden.  
 
The Olafia clinic was responsible for recruiting pre-selected patients, and the collection and 
distribution of clinical samples in this study. The Department of Microbiology Ullevål 
University hospital was responsible for diagnosing gonorrhoeae from the clinical samples by 
using their routine culture diagnostic tools. The Department of Microbiology and Infection 
control developed and performed the porA in-house PCR, and was responsible for the 
collection of data and evaluation of the clinical validation. 
Test results from each laboratory were compared after enclosure of the study. The clinical 
validation was performed by comparing the results from the porA PCR with the results from 
the phenotypic diagnostic. In cases of discrepancy between the results, an aliquot of the 
clinical samples was sent to Örebro for sequencing analysis. 
 
4.5 Interpretation of diagnostic data 
An evaluation of the analytic sensitivity of the porA PCR was done before running the PCR 
with clinical samples. After the clinical validation was ended the diagnostic sensitivity and 
specificity was calculated for both porA PCR and phenotypic diagnostic techniques. In 
addition the positive predicative value (PPV) and negative predicative value (NPV) was 
calculated for both methods. 
• Analytic sensitivity is the number of samples identified as positive by the method.  
• Diagnostic sensitivity is the number of individuals with a disease that is detected by 
the method.  
 
• Analytic specificity is the number of true negative samples detected by the method. 
Diagnostic specificity is the number of healthy individuals detected by the method. 
• PPV indicates how often test positives are positive. 
• NPV predict how often test negatives are negative. 
• Prevalence indicates the distribution of disease within a study population.  
















5.1 porA pseudogene primers  
The alignments and design of primers and probes were performed by Stig Ove Hjelmevoll25. 
The primers, probe and amplicon were aligned to all available sequences deposited in 
GenBank®. The forward primer shared greatest homology to Yersinia species, while the 
reverse primer showed similarity to Homo sapiens chromosome 11 clone fa0692. The probe 
had a 23 of 30 bp similarity to N. meningitidis. Blasting the entire amplicon showed a 
homology in 58 of 102 bp of the porA gene found in N. meningitidis.  As shown in figure 4 
the porA gene found in N. meningitidis and porA pseudogene found in N. gonorrhoeae is 
sufficiently different and can be used to discriminate the two bacteria. In addition this figure 




Figure 4: The image show a nucleotide sequence alignment of a partial N. gonorrhoeae consensus porA 
pseudogene compiled from 87 sequences and the corresponding N. meningitidis sequence. The boxed sequences 
on the flanks are the forward and reverse primer location, respectively. The boxed sequence in the middle is the 
location of the probe. The MC58 sequence is the partial porA sequence of the previously published whole-




5.2 Technical performance of porA PCR 
As previous described, the porA primers amplify a 102 base pair (bp) fragment of the porA 
pseudogene. The porA primers and probe were optimized as recommended by Applied 
Biosystem, and a final concentration of 900 nM primer and 200 nM probe was found to be 
optimal. The final concentration of the IAC probe was 100 nM. The amount of IAC added in 
the porA reaction solution was not quantified, but optimized to give approximately a cycle 
threshold value form 36 to 39 in known negative samples.  
 
To test efficiency of the optimized reaction solution, quantified N. gonorrhoeae DNA, was 
diluted in a ten-fold dilution series to generate a standard curve by using the software 
available in SDS ABI 7900 HT. This is illustrated in figure 5. The slope value in the figure is 




Figure 5: Standard curve made by using the software for ABI SDS 7900 HT® based on data from dilution series 




 The efficiency of the porA PCR, when IAC was added to reaction solution, showed an 
amplification efficiency of 99.3%, and the amplification efficiency without the IAC was 94.9 
%. Figure 6 shows the difference between the reaction solution with and without IAC, the 4.4 
% difference in amplification efficiency is insignificant. The curves in the plot are 
approximately equal in each dilution and this indicates that the presence of IAC in the 





 Figure 6: Curves generated from making a dilution series of quantified N. gonorrhoeae DNA and two different 
reactions solutions with and without IAC. There are four parallels for each dilution, hence two parallels for each 
reaction solution. There were insignificant differences in the amplification of DNA.  
 
 
Detection limit was also determined by using dilution series of the quantified N. gonorrhoeae 
DNA from Tebu-bio. As an example, figure 7 shows the results of a dilution series of the 
quantified DNA and according to the curves the PCR has a good linearity.  In 5 of 5 parallel 
reactions the porA PCR detected 7.5 genome equivalents (Geq)/PCR reaction, and this was 
concluded as the lower detection limit. No upper limit was determined for the porA PCR. 
However, the porA PCR also detected 1.5 Geq/PCR reaction in 3 of 5 parallel reactions, 
indicating that the porA PCR is able to amplify even lower amounts of N. gonorrhoeae DNA 




Figure 7: The figure illustrates the linearity of a dilution series of quantified N. gonorrhoeae DNA from Tebu-
bio with the porA PCR. 
 
 
To determine the robustness of the porA PCR, the reaction solution volume was held constant 
at 13.5 µl while the template volume varied from 9 to 15 µl. When using a low and a high 
concentration of quantified N. gonorrhoeae DNA and a NTC as shown in figure 8 the varying 
template volume showed insignificant differences in the cycle threshold values. This indicates 
that the PCR reaction will be equally efficient even if the template volume increase to 15 μl, 
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To evaluate the recovery of DNA during the isolation procedure a dilution series of N. 
gonorrhoeae spiked in UTM-RT medium were plated in duplicates and the PCR was also run 
in parallels. The number of colony forming units/ml was 80 in the first experiment, and the 
second experiment resulted in 53. When translated to colony forming units/μl DNA eluate this 
gives 0.13 CFU/μl DNA eluate, meaning a 100 % recovery in the DNA isolation 25.   
 
 
Before running the porA PCR with clinical samples, the DNA from several international 
Neisseria reference strains, clinical isolates and heterogeneous control strains were analyzed. 
This was done to estimate the analytic sensitivity and specificity of the porA PCR.  
The PCR results from 44 Neisseria references strains, 168 clinical isolates and 46 
heterogeneous control strains listed in table 7, 8 and 9.  
A positive result indicates amplification by the porA primers, and presence of the porA 
pseudogene in the DNA. A negative result indicates no amplification by the porA primers and 
no porA pseudogene detected. 
 
 
Table 7: International Neisseria reference strains analyzed with the porA PCR and PCR 
results. 
Reference strain* Number of strains Positive PCR Results   Negative PCR Results   
Neisseria  gonorrhoeae 32 32 0 
Neisseria meningitides 4 4 0 
Neisseria sicca 2 2 0 
Neisseria subflava 1 1 0 
Neisseria flavescens 1 1 0 
Neisseria mucosa 2 2 0 
Neisseria lactamica 1 1 0 
Neisseria cinera 1 1 0 
Total 44 44 0 
*The reference number for each strain is previous listed in table 1. 
 
 
Table 8: Clinical isolates analyzed with the porA PCR and PCR results.  
Clinical isolate Number of isolates Positive PCR Results   Negative PCR Results   
Neisseria  gonorrhoeae 168 168 0 
Neisseria gonorrhoeae 
subspecies kochii 
4 4 0 
Neisseria meningitides 7 0 7 
Neisseria sicca 7 0 7 
Neisseria subflava 11 0 11 
Neisseria flavescens 3 0 3 
Neisseria mucosa 5 0 5 
Neisseria lactamica 7 0 7 
Neisseria cinera 7 0 7 
Neisseria cavicae 1 0 1 
Neisseria animalis 1 0 1 
Neisseria polysaccharea 1 0 1 








Table 9: Heterogeneous control strains analyzed with the porA PCR and PCR results.  
Heterogeneous strains* Number of isolates PCR results Positive  PCR results Negative  
Gram negative bacteria 18 0 18 
Gram positive bacteria 23 0 23 
Fungus 1 0 1 
Viruses 4 0 4 
Total 46 0 46 
*More details about the isolates are previously listed in table 2. 
 
 
None of the reference strains, clinical isolates or the heterogeneous control strains analyzed 
by the porA PCR gave unexpected results. All of the reactions containing N. gonorrhoeae 
DNA were amplified by the primers indicating that all of the tested N. gonorrhoeae strains 
possess the porA pseudogene. The DNA from strains and isolates, other than N. gonorrhoeae, 
were not amplified. The IAC was amplified in all negative reactions and indicated no 
inhibition in any of the PCR reactions. However, it unlikely that eluated DNA from the above 
mentioned material contains inhibitory contaminants, considering they all are pure isolates. 
In each DNA isolation and PCR set up, controls were used to monitor the protocols. ATCC 
19424 N. gonorrhoeae as PPC, and water as NPC. In addition each PCR set up was run by 
including a purified DNA from N. gonorrhoeae as PTC, and water as NTC. PPC, NPC, PTC 
and NTC were consistently evaluated before the other results, and if they passed, an 
evaluation of the other reactions followed. The PPC, NPC, PTC and NTC gave expected 


























Figure 9: Cycle threshold values from PPC, NPC, PTC and NTC from 10 independent analyses.  
 
In figure 9 the cycle threshold values (average value of 2 parallels) from PPC, NPC, PTC and 
NTC from 10 independent analyses of clinical samples are plotted (Isolation of DNA and 
PCR was performed within the same day). Three different batches of reaction solution are 
used, but same batches of PPC, NPC and NTC was used in all 10 analyses. A new batch of 
PTC was used after analysis A4, and explains the increase in cycle threshold value. The plot 
of NPC and NTC should preferably achieve equal cycle threshold values, since reagents and 
contaminants during the isolation process should not interfere with the pureness in the DNA 
eluate. The plot indicates stability in both isolation process and PCR set up. 
 
In overall, the porA pseudogene porA PCR has shown a 100 % analytic sensitivity and 






5.3 Functionality of UTM-RT system  
To test the suitability for the transport media, a low and high dilution of the ATCC 19424 (N. 
gonorrhoeae) were added to the buffer. After storage in different temperatures, isolation of 
DNA and porA PCR were performed after 1, 3 and 7 days. The results are presented in Table 
10. 
 
Table 10: Cycle threshold values achieved for the ATCC 19424 N. gonorrhoeae inoculated in 
UTM RT. 
ATCC 19424 inoculated in 
UTM-RT 
1 day Cycle threshold 
value* 
3 days Cycle threshold 
value* 




27,8 27,9 27,9 
Dilution 10-1 
+ 4˚C 
26,9 27,5 27,6 
Dilution 10-4 
Room temperature 
37,8 36,8 37,6 
Dilution 10-4 
+ 4˚C 
38,3 39,1 37,2 
*The cycle threshold value is an average value from three reactions. 
 
There were insignificant variations in cycle threshold values for the low and high dilution of 
the ATCC 19424 when analyzed after 1, 3 and 7 days. This indicates that the UTM-RT is a 








5.4 Diagnostic validity 
In total 360 samples from 242 individuals were included in this study, 185 males and 57 
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Figure 11: Distribution of different sample sites in male and female included in this study. 
 
The porA PCR identified N. gonorrhoeae in 52 samples while phenothypic techniques 
identified N. gonorrhoeae in 37 samples. All 15 samples in discrepancy were confirmed as 
true positive by sequencing the 16S rRNA and the porA pseudogene. Table 11 shows the 
distribution of samples with N. gonorrhoeae positive porA PCR, compared with results from 
phenotypic identification.  
In other words, based on the results from porA PCR, phenotypic diagnostic tools and the 
results from the sequencing, 308 samples were concluded as true negatives and 52 samples, 











Table 11: Distribution of porA PCR positive samples in different sample sites. 
Sex PCR Ph. Tech.* Urethra Rectum Pharynx Cervix Total 
Positive Positive 26 5 2 0 33 
Male 
Positive Negative 1 6 8 0 15 
Female Positive Positive 1 0 0 3 4 
Total 28 11 10 3 52 
* Phenotyp. Tech = Phenotypic techniques 
 
 
Based on this data the porA PCR has a 100 % diagnostic sensitivity and specificity, and 
respectively 100 % for the PPV and NPV. The prevalence of gonorrhea in the study 
population was 14.78 %. 
Approximately 76% of the included individuals were males, and the prevalence for gonorrhea 
among males was 17.4%. The prevalence in tested females was 5 %, but the number of tested 
females has no good statistical basis due to limited individuals tested. 
In comparison, the cultivation techniques did not identify 14 individuals as gonorrhea 
positive. The sensitivity was 71 %, while specificity was 100 %. The PPV was 100 % and the 
NPV 93 %. 
 
The internal amplification control was amplified in all of the 308 negative samples except for 
35. 
Table 12: Distribution of samples with inhibition. 
Sex Urethra Rectum Pharynx Cervix Total 
Male 11 6 11 0 28 
Female 2 0 1 4 7 
Total 13 6 12 4 35 
  
Table 12 show number of samples with inhibition during this study, and the sampling sites; 
urethra (n =13), rectum (n= 6), pharynx (n =12), and cervix (n =4). These samples were 
isolated once more undiluted and diluted 1:2 and then retested. All samples were concluded as 
 
true negative after retesting them, there were no detection of N. gonorrhoeae and the IAC was 
amplified. 
However, 42 samples from 27 patients were excluded in the study. The reasons for exclusion 
were:  
• Samples sent for test of cure after treatment (n=21). 
• Samples sent for Herpes simplex virus testing (n=7). 
• Mechanical failure of the DNA preparation robot, Tecan miniprep-75 (n=14). 
 
As mentioned, PPC, NPC, PTC and NTC were also included during clinical validation. The 
controls were consistently evaluated before sample results, and if they passed an evaluation of 
the results followed. The PPC, NPC, PTC and NTC gave expected results in each run,  






















The results from the technical and clinical validation of N. gonorrhoeae porA pseudogene real 
time PCR 27, indicate that the method is species specific for N. gonorrhoeae. All of the 200 N. 
gonorrhoeae reference strain and gonococcal clinical isolates were detected by the porA PCR. 
In addition neither the heterogeneous control strains nor the commensal Neisseria was 
amplified. The porA PCR achieved 100 % specificity and sensitivity in the material tested 
here in comparison to culture and phenotypical diagnostics.  
 
6.1 A species specific target 
The success of designing a species specific PCR depends on finding an appropriate target 
sequence. The primers and probes showed low similarity to other sequences deposited in 
GenBank®. Despite of the great similarity between N. gonorrhoeae and N. meningitidis, the 
alignments of the N. gonorrhoeae porA pseudogene consensus sequence and porA gene found 
in N. meningitidis showed a sufficient diversity within the genes to discriminate the two 
bacteria. Even so, when using sequencing data to find regions of local similarity between 
genomic sequences, it is important to consider that the results purely depend on the 
information stored in the databases. And as for the Neisseria, it is important to bear in mind 
that several commensal Neisseria species are not fully sequenced, and that they are highly 
transformable organisms.  
However, the primers and the probe were located in a conserved region of the porA 
pseudogene. This is beneficial since conserved regions may indicate that they have been 
maintained during species evolution. All N. gonorrhoeae examined in this study were 
amplified by the porA primers, indicating they all possess the porA pseudogene.  Furthermore, 
the analyzed N. gonorrhoeae strains had been isolated over 5 decades (from 1960 to 2006). 
This indicates that the target region of the porA pseudogene has been stable over the past 5 
decades. 
Other studies have reported presence of porA pseudogene in  N. gonorrhoeae from different 
geographical regions, as well as absence in commensal Neisseria 28, and suggesting that it is a 
suitable target for identifying N. gonorrhoeae. In addition, previous sequencing of the entire 
porA pseudogene has showed a distinct diversity from the porA gene in N. meningitidis 13.  
The lack of porA pseudogene expression in N. gonorrhoeae may protect this gene from 
changes since it is not subjected to evolutionary pressure. However, bacteria are known to 
 
only retain genomic material that is beneficial. Why the N. gonorrhoeae possess this 
pseudogene is unknown, but there might be a reason for keeping it.  
 
6.2 Assay validity 
There are other aspects influencing the development of an in-house PCR, such as finding 
optimal primer and probe concentrations, and achieving an acceptable efficiency and 
detection limit. 
Regarding the PCR efficiency two aspects of the PCR protocol should be considered, the 
components in the reaction solution and the equipment. Insufficient concentrations of primers 
and probe, long amplicons and primer dimmers will influence the efficiency. To reveal primer 
dimmer, the target primers were tested by using SYBR® green (data not shown in the thesis), 
and non unspecific products were observed. In this study a majority of components in the 
TaqMan® Fast Universal PCR Master Mix were already optimized by the manufacture, 
making the optimization less laborious. All primer/probe concentrations and amplicon size 
were according to manufacture guidelines, and the optimized reaction solution was considered 
both robust and efficient.  
The diagnostic value of an assay depends on the ability to produce result of certain stability. 
By including known control parameters in each step of the assay the robustness was 
monitored. Processing controls was included in the isolation of DNA, both positive and 
negative controls. In addition positive and negative template controls was analyzed in each 
PCR setup. However, all controls showed stable values (in this case cycles threshold values) 
during the study, indicating robustness in the machinery as well as in the reaction solution. 
The use of known positive controls is crucial when analysing only negative samples. 308 
samples were concluded as true negatives in this study, and in several isolation processes and 
following PCR setups there were no positive clinical samples. 
In addition the robustness of the reaction solution was also tested by using a low and high 
concentration of purified N. gonorrhoeae DNA. Variations in the template volume had 
insignificant impact on the cycle threshold value, for both low and high concentration.  
Also, the IAC controls the PCR reaction solution which function is to detect the presences of 
inhibitory contaminants. Inhibition of the PCR reaction was observed in 35 of 308 negative 
clinical samples, but after retesting they were concluded as true negatives. 
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 The amount of IAC added in the reaction solution was not quantified, but it was optimized to 
give a cycle threshold value from 36 to 39 in known negative samples. The attempt was to 
keep the amount as low as possible to avoid competition of target primers in samples 
containing low amount of target DNA. Since the IAC is a PCR product it might influence the 
efficiency of the PCR, hence efficiency was determined with and without the presence of 
IAC. As shown, the porA PCR efficiency in the presence of IAC were 99.3%, while without 
IAC it was 94.9% 27, indicating that the IAC has little influence on the efficiency.  
Regarding the amount of target DNA, the detection limit of the assay decides whether it is 
detected or not. The porA PCR had a detection limit of 7.5 Geq/PCR reactions, and this is 
considered low. The limit of detection was reproduced in three separate runs. As a curiosity 
the porA PCR was also able to detect 1.5 Geq/PCR reaction, but the detection was not 
consistent. Even so, this indicates the possibility to detect even lower amounts of DNA than 
the settled detection limit. Samples containing large amount of DNA will inhibit the PCR 
reaction and this would be uncovered by the IAC in reaction solution, hence an upper 
detection limit was not determined.  
 
Several pathogenic and non-pathogenic micro-organisms as well as N. gonorrhoeae reference 
strains and gonococcal isolates were included to evaluate the specificity of the assay. We 
attempted to include representative organisms found in the normal flora in locations N. 
gonorrhoeae colonizes; cervix, urethra, rectum and pharynx. In addition we tested DNA from 
organisms, which already had established NAATs in our laboratory. None of the bacteria and 
viruses examined was amplified by the porA primers, and all of the 200 N. gonorrhoeae 
reference strains and gonococcal isolates examined in this study were identified by the porA 
PCR.  
 
With the above mentioned satisfying results, the porA PCR showed potential for being 




6.3 DNA preservation 
The molecular approach in the attempt of diagnosing gonorrhea demanded a different 
transport media than what already existed in our laboratory. The UTM-RT was suitable for 
pathogens with already established NAATs, but had not been evaluated to transport N. 
gonorrhoeae by the manufacture. Regarding the variation in temperatures during transport 
and also the transport duration, inoculated UTM was stored both at room temperature and at 
4ºC.  Further it was tested after 1, 3 and 7 days of storage. The UTM-RT was found suitable 
for preservation of gonococcal DNA, and the DNA was not degraded even when stored for 7 
days.  Unfortunately N. gonorrhoeae does not recover from the UTM-RT, so a separate 
sample-swab for phenotypic detection and susceptibility testing is still necessary.   
 
6.4 Diagnostic validity 
The analytic sensitivity and specificity of the porA PCR was 100 %. Even so, the use of 
reference strains and isolates to determine these parameters can never replace the value of 
testing biological samples. Clinical samples contribute to testing of biological variation in the 
sample (host), which can not be done when using pure isolates. To achieve significant 
statistical values, the number individuals in the study population are of importance. In this 
study 360 samples from 242 individuals were analysed. Statistically it would have 
strengthened the clinical validation if a greater number of individuals had been possible to 
include. In addition the samples were taken from individuals attending only one clinic, from 
the same geographic region, and a possible diversity among gonococcal strains from other 
regions was not considered. To include more individuals in the study population and sampling 
from different geographic areas would improve the validation of porA PCR. However 
gonorrhoeae is rare in Norway and the population available is therefore limited.  
 
The porA PCR showed a 100 % diagnostic sensitivity and specificity, while the phenotypic 
identification achieved a sensitivity of 71 %, and the specificity was equal to the porA PCR‘s 
specificity. The clinical validation was in favor of the porA PCR which achieved a greater 
sensitivity than the cultivation techniques. The porA PCR identified further 14 more cases of 
gonorrhoeae. To resolve discrepancy, all samples were examined by sequencing of the entire 
porA pseudogene to state the presence of gonococci, and since the PCR targets the porA 
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pseudogene, sequencing of the 16S rRNA was also performed  27 to strengthen the discrepant 
resolution. In the end, all discrepant samples were concluded as true positives.  
However, the discrepants were sampled from pharynx and rectum, and N. gonorrhoeae 
recover poorly from these sample sites compared to sampling from urogenitalia 15. The cause 
of false- negatives from the cultivation techniques could also have been due to transport 
conditions. But the sampling clinic (Olafia clinic) attempt to store samples for cultivation 
maximum 3 hours in room temperature before sending them to microbiology laboratory. In 
addition, the laboratory which performed the phenotypic identification (Ullevål University 
Hospital) is located only 3 km in distance from the clinic. This is an advantage regarding the 
survival of N. gonorrhoeae, but this is rarely the situation for general practitioners or clinics, 
which in Norway often are located far from the laboratory. Another reason to the false 
negative results can be explained by possible overgrowth of other micro organisms from the 
normal flora31. This is often the problem when cultivation from pharynx and rectum. 
Regarding gonococcal infection in these sites, they are often asymptomatic, and valid 
diagnostic tools are essential to identify N. gonorrhoeae. Our results indicate that the porA 
PCR can improve diagnosis of gonorrhea in these sites.  
 
Nevertheless, false-positive diagnosis of gonorrhea might occur particularly from pharynx 
samples. The commensal Neisseria species and N. meningitidis are most common in the 
pharyngeal mucosa, which gives a greater risk for assay cross reactivity when analyzing 
samples from pharynx. But there has been reports of N. cinera, N. lactamica, N. sicca and N. 
subflava isolated from genital mucosa 1,29, indicating a possibility of false-positive diagnosis 
if the method does not adequately distinguish gonorrhoeae from commensal Neisseria, even 
in genital samples. False positive results have also been reported for many of the commercial 
NAATs 1,14,29, and this was also the case when we tested other genes as targets for detection 
of N. gonorrhoeae. Before choosing the porA pseudogene, TraG and TraH, dcmG, carbonic 
anhydrase, and pJDI 25 were tested but none of them were species specific. Their either 
misclassified commensal Neisseria as N. gonorrhoeae or the N. gonorrhoeae was not 
identified.  A misdiagnosing of gonorrhoeae can have a major impact on the individual. A 
false positive diagnosis can be social devastating for individuals living in a partnership, while 
a false negative diagnosed individual will continue as a reservoir for the gonococci.  
 
A good discriminatory tool for diagnosing gonorrhea is crucial, to avoid false positive as well 
as false negatives result. The evaluation of the porA PCR has so far shown that is suitable for 





The major objective in this study was to establish a sensitive and specific PCR for detection 
of N. gonorrhoeae.  
The specificity of the primers showed that the design was successful. Choosing the porA 
pseudogene as target and locating the primers in a conserved region of the gene resulted in 
amplification of only DNA from N. gonorrhoeae.   
 
The technical validation of the porA PCR gave an acceptable result. The optimized reaction 
solution had a final concentration of 900 nM primers, 200 nM porA probe and 100 nM of the 
IAC probe, and efficiency was 99.3 % even in the presence of an IAC.  The 7.5 Geq/PCR 
reaction detection limit is considered low. And 100 % analytic sensitivity and specificity is 
acceptable. All of the 200 different strains and isolates of N. gonorrhoeae were amplified by 
the porA primers, and neither of commensal Neisseria strains and other micro organisms 
tested was identified as N. gonorrhoeae.   
The UTM-RT system is already in use as transport system for Chlamydia trachomatis, Herpes 
Simplex I/II and Adenoviruses. We found it suitable for preserving N. gonorrhoeae DNA after 
7 days and in different temperatures. The system comprises of a variety of swab suitable for 
different gonococcal samples sites.  
The clinical validation resulted in 100 % specificity and sensitivity for the PCR in comparison 
to culture (71 % sensitivity). The real-time PCR assay may therefore increase sensitivity in 
supplement to culture. The PPV and NPV were also 100 % in comparison to culture in this 
study population. A high PPV and NPV are important, especially in low prevalence 
populations such as Norway.  
In overall, the work presented show when analyzing samples from the selected population the 
porA PCR can increase the sensitivity in sites as pharynx and rectum compared to cultivation 
techniques. Throughout the study the porA PCR has shown sufficient assay stability, it is 
rapid and reproducible. The porA pseudogene has so far proved to be highly species specific 





8 FUTURE  PERSPECTIVES 
The porA pseudogene PCR has so far proved to be a valid supplement in diagnosing 
gonorrhoeae. However, it would be of interest to further evaluate the PCR. A thorough 
validation by including study populations from different geographical areas over a long time 
period is necessary. In fact, the method is in use at several places around the world and was 
recommended by centers for disease control and prevention (Atlanta, Georgia) to their 
collaborators in Thailand. In addition, after antibiotic treatment of gonorrhoeae, a test of cure 
is done, prompting the need to find the appropriate time for a test of cure when diagnosing 
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